
<HTML>
<HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">
<FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5">
<B>FORM 8-K </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<HR WIDTH="17%"SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">
<B>CURRENT REPORT</B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3">
<B>PURSUANT TO SECTION 13 OR 15(d)<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">
<B>Date of Report (Date of Earliest Event Reported) &#150; December 27, 2004 </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>
WEST PHARMACEUTICAL SERVICES, INC.<BR>
<BR><FONT FACE="Times New Roman" SIZE="3"></FONT>
(Exact name of registrant as specified in its charter) </B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center"> <TR> <TD WIDTH="34%"></TD> <TD
VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="32%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD
WIDTH="32%"></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Pennsylvania</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1-8036</B></FONT></TD> <TD VALIGN="bottom"><FONT
SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>23-1210010</B></FONT></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other
jurisdiction<BR>
of Incorporation)</B></FONT></P>
</TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top" ALIGN="center"> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS
Employer</B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P>
</TD></TR> </TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center"> <TR> <TD WIDTH="50%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD>
 <TD WIDTH="48%"></TD></TR> <TR> <TD VALIGN="top" ALIGN="center">
<FONT FACE="Times New Roman" SIZE="2"><B>101 Gordon Drive, PO Box 645, Lionville, PA</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD
VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>19341-0645</B></FONT></TD></TR> <TR> <TD
VALIGN="top" ALIGN="center">

<FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive
offices)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> <TD VALIGN="top"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR> </TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">
<B>610-594-2900</B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not Applicable
</B></FONT></P>

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>(Former name or address, if changed since last report) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px">

<FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT
FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD> <TD
ALIGN="left" VALIGN="top">

<FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <p Style='page-break-before:always'>




<!-- MARKER FORMAT-SHEET="Para Hang" FSL="Default" -->
<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A001></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 1.01 Entry into a
Material Definitive Agreement. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On December 24, 2004, West
Pharmaceutical Services, Inc (&#147;West&#148;) entered into a Share and Asset Purchase
Agreement (the &#147;Agreement&#148;) to sell its Drug Delivery business to a new company
formed by Warburg Pincus Private Equity VIII and Warburg Pincus International Partners to
facilitate the acquisition. As announced on June 30, 2004, West intends to concentrate
resources on its core Pharmaceutical Systems business and was evaluating strategic
alternatives for the Drug Delivery business that would provide for its near term funding
needs and long term success. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Under the terms of the Agreement, the
new company will purchase all of the shares of West&#146;s wholly owned subsidiary in
Nottingham, United Kingdom and certain assets in the United States which collectively
represent West&#146;s Drug Delivery business. The Drug Delivery business consists of the
business of researching, developing, licensing and marketing systems for the delivery of
therapeutic compounds for sale throughout the world covering a range of delivery technologies
for various types of administration, including, nasal, oral and parenteral, and products
that incorporate these technologies in each case that employ West's patented or
proprietary chitosan or pectin nasal technology or starch-capsule coating oral technology
and the business of developing a generic manually administrable fluticasone product.
At the closing date of the Agreement, West
will receive cash proceeds of $7.1 million and a 14% ownership interest in the new
company. In addition, West is entitled to 3% of any future royalty income resulting from
the commercial success of the technologies contributed to the new company. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>As a result of the transaction, West
will record a pre-tax charge in the range of $4.0 million to $7.0 million ($0.08 to
$0.16 per diluted share) consisting of severance, transaction and other exit costs
estimated at $3.9 million and potential asset impairment charges. The results of the Drug
Delivery Systems segment, including the loss on disposal, will be reported as discontinued
operations in West&#146;s subsequent financial reports. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Agreement is subject to customary
closing conditions, which are expected to be satisfied within 30 days of the signing of
the agreement. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On December 27, 2004, West issued a
press release announcing the signing of the Agreement. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by
reference. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A002></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 2.05 Costs
Associated with Exit or Disposal Activities. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information contained in item
1.01 above is hereby incorporated by reference. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;
          In connection with the Agreement to sell the Drug Delivery business to the new
          company, West will incur employee termination and other exit costs, primarily in
          the United States related to operations that will not be assumed by the new
          company. These actions will be completed by December 31, 2004. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>b)&nbsp;&nbsp;&nbsp;&nbsp;
          The major costs expected to be incurred in connection with the Agreement are
          listed below: </FONT></P>
<pre>
Severance costs                                      $1.9 million
Legal fees and other transaction costs               $1.0 million
Pension plan curtailment charge                      $0.5 million
Contract termination and laboratory exit costs       $0.5 million
</pre>
<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>c)&nbsp;&nbsp;&nbsp;&nbsp;
          The total costs associated with the Agreement to dispose of the Drug Delivery
          business are estimated at $3.9 million. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>d)&nbsp;&nbsp;&nbsp;&nbsp;
          West estimates that $2.9 million of the costs expected to be incurred will be
          paid in cash. The remaining $1.0 million of non-cash charges are associated with
          stock based severance compensation and pension plan curtailment charges. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A003></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Item 2.06 Material
Impairments. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information contained in item
1.01 and 2.05 above is hereby incorporated by reference. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;
          On December 24, 2004 West agreed to sell its Drug Delivery business to a new
          company in return for cash and a 14% ownership interest in the new company. In
          addition, West has also determined that it will dispose of its Clinical Services
          unit component of the Drug Delivery segment and has classified those assets as
          being held for sale or other disposition. Preliminary analysis of the fair value
          of the Clinical Services business, the 14% interest in the new company and the
          recovery value of certain equipment retained by West has been performed
          indicating a maximum pre-tax impairment charge of $3.1 million. The final
          determination of the impairment charge, if any, will be made upon the completion
          of the fair value analysis and any related disposition agreements. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->

<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Item
9.01 Financial Statements and Exhibits.</FONT></H1>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(c)&nbsp;&nbsp;&nbsp;&nbsp;
          Exhibits </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left" FSL="Default" -->
<A NAME=A005></A>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;99.1
Press Release dated December 27, 2004 </FONT></P>

<BR>

<HR SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0"WIDTH="40%" BORDER="0"> <TR> <TD WIDTH="100%"></TD></TR> <TR> <TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><u>

WEST PHARMACEUTICAL SERVICES</u></FONT></P><br> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">
/s/ Joseph E. Abbott</FONT></P>
<HR WIDTH="72%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR> <TR> <TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">

Joseph E. Abbott</FONT></TD></TR> <TR> <TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">
Vice President and Corporate Controller</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">December 27, 2004 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<HR SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Exhibit Index</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.1&nbsp;&nbsp;&nbsp;&nbsp;
West Pharmaceutical Services, Inc. Press Release, dated December 27, 2004. </FONT></P>


</BODY>
</HTML>

